Veeva Systems was sued by IQVIA for allegedly gaining unauthorized access to IQVIA’s proprietary physician visit data and healthcare provider intelligence—data that Veeva then used to compete against IQVIA in selling software to life sciences sales teams. The eight-year legal battle between these data giants culminated in an August 2025 settlement, with Veeva agreeing to pay approximately $31 million in attorneys’ fees and both companies establishing new data-sharing agreements. This case represents one of the most significant intellectual property disputes in the life sciences technology sector, touching on questions of competitive fairness, data access rights, and how pharmaceutical companies monitor sales representatives in the field. The lawsuit, filed in 2017 and formally titled IQVIA Inc. et al v. Veeva Systems Inc.
(No. 2:2019cv15517, D.N.J.), grew out of competing business models in the same market. IQVIA had built its data products on proprietary information about physician visits and healthcare provider relationships—exactly the kind of intelligence that sales representatives and pharmaceutical companies rely on to target their marketing efforts. IQVIA alleged that Veeva intentionally accessed this confidential data without authorization to build competing products. The resolution of this case established new boundaries around data sharing in the life sciences industry and resulted in both companies implementing formal agreements to govern how they share platform access going forward. This article explains what the lawsuit actually alleged, how the two companies competed, why the case took eight years to resolve, and what the settlement means for data security and competitive practices in pharmaceutical technology.
Table of Contents
- What Did IQVIA Claim Veeva Systems Did With The Data?
- How Did Veeva Systems Compete in This Space, and Why Would They Need This Data?
- What Was The Scope Of The Lawsuit, And What Companies Were Involved?
- What Did The Settlement Require Veeva Systems To Do?
- What New Arrangements Did Veeva And IQVIA Establish After The Settlement?
- What Does This Settlement Mean For Data Security In The Pharmaceutical And Life Sciences Industry?
- What Lessons Does This Case Offer For Companies Managing Proprietary Data?
What Did IQVIA Claim Veeva Systems Did With The Data?
IQVIA’s core allegation was that Veeva Systems gained unauthorized access to IQVIA’s proprietary physician visit data and used it to improve its own software and data products. The data at the center of the dispute wasn’t financial information or trade secrets in the traditional sense—it was behavioral data: which doctors were visited by which pharmaceutical sales representatives, how often those visits occurred, and detailed profiles of healthcare providers based on their specialties and practice patterns. This kind of data is the lifeblood of sales intelligence in the pharmaceutical industry. Sales teams use it to plan territory assignments, identify high-value targets, and measure the effectiveness of their field activities. IQVIA alleged that the access was intentional and strategic. Rather than licensing this data through normal commercial channels, IQVIA contended that Veeva deliberately tapped into IQVIA’s systems to extract the information, then used it to build competing products that offered similar capabilities to pharmaceutical companies.
For a sales intelligence company, this would be a catastrophic breach of trust—like discovering that a competitor had broken into your secure facility and photocopied your customer lists and strategic plans. The claim suggested Veeva was not just competing fairly on product quality but was gaining an unfair advantage through unauthorized access to a competitor’s most valuable assets. However, Veeva disputed these allegations. The company countered with its own lawsuit claiming that IQVIA was abusing monopoly power in the data market and unfairly restricting Veeva’s access to the information it needed to compete. Veeva’s position was that IQVIA had locked up physician visit data through exclusive arrangements and that Veeva was simply trying to level the playing field. This counterclaim suggests that the underlying dispute was about market access, not just intellectual property theft—a nuance that complicates the narrative of a simple data heist.
How Did Veeva Systems Compete in This Space, and Why Would They Need This Data?
Veeva Systems is best known as the leading provider of customer relationship management (CRM) software for the pharmaceutical and life sciences industries. Their platform helps sales forces track interactions with healthcare providers, manage territory assignments, and analyze the effectiveness of their sales efforts. Veeva’s software is powerful and widely used, but IQVIA’s data product gives IQVIA an advantage in a complementary market: the underlying intelligence that tells sales teams who to target and when. The competitive dynamic at the heart of this lawsuit was about vertical integration and data control. IQVIA operated as both a data provider and a competitor to Veeva’s CRM customers. IQVIA could tell a pharmaceutical company exactly which doctors were being visited by competitors and how often, which could inform that company’s own sales strategy.
Veeva, meanwhile, collected data about which doctors were visited by its CRM users, but it didn’t have independent access to comprehensive industry-wide data on physician visits. If Veeva had access to IQVIA’s complete dataset, it could offer customers more valuable competitive intelligence without relying on IQVIA as a third-party data vendor. However, if X company wanted to use Veeva’s software without sharing data with IQVIA, they would be blind to what competitors were doing. This created a natural tension: Veeva wanted to offer customers the ability to see the full competitive picture, which meant needing access to the same data IQVIA controlled. The unauthorized access allegation suggests that instead of negotiating for that data legally, Veeva allegedly took it directly. Whether that’s true or not, the lawsuit illustrates a fundamental challenge in data-driven industries: when two companies compete, and one controls proprietary data, who gets to decide how that data is shared?.
What Was The Scope Of The Lawsuit, And What Companies Were Involved?
The lawsuit named IQVIA and multiple related IQVIA entities on the plaintiff side against Veeva Systems. This wasn’t a small dispute between two individual employees or a single product line—it was a multi-party litigation involving the corporate entities most directly responsible for the products and business practices in question. The federal court in New Jersey handled the case, giving it jurisdiction over both companies’ operations in that district and their interstate commerce activities. The case ran for eight years, from 2017 through August 2025, which is a significant timeline that reflects the complexity of the underlying disputes and counterclaims. During those eight years, discovery would have involved extensive document production, depositions of key employees, and battles over what evidence was relevant and what was confidential.
For a case involving proprietary data and source code, discovery battles alone can consume years as both sides fight over what counts as trade secrets and what can be safely shared with opposing counsel. The fact that the case dragged on for eight years before settlement doesn’t necessarily mean either side was winning. Complex intellectual property cases often take years to litigate because the technical and legal issues are genuinely difficult to resolve. A jury might struggle to understand exactly what data was accessed, whether the access was “unauthorized,” and what damages resulted. Settlement, in this context, may have reflected mutual uncertainty about outcome and a rational decision by both sides to move forward with a new business arrangement rather than continue burning legal fees.
What Did The Settlement Require Veeva Systems To Do?
The settlement announced in August 2025 required Veeva to pay approximately $31 million—but notably, not to IQVIA as damages for the alleged data breach. Instead, the money went to the law firms representing the parties, as attorneys’ fees. This is an unusual provision that suggests both sides may have been represented by high-powered counsel that negotiated aggressively for compensation, and it reflects the reality that eight years of litigation generates enormous legal bills. Critically, the settlement did not include damages paid from Veeva to IQVIA. All claims and counterclaims were dismissed with prejudice, meaning neither company is required to pay the other monetary damages. This structure suggests that rather than one party “losing” the case and paying damages, the settlement was more of a mutual reset.
IQVIA wasn’t awarded compensation for the data it alleged Veeva stole, and Veeva wasn’t forced to admit liability. Instead, both companies agreed to dismiss the litigation and establish new contractual relationships that would govern how they work together going forward. This outcome illustrates an important principle in settlement negotiations: sometimes dismissing a case “with prejudice” (meaning the claims can’t be refiled) with mutual non-admission of liability is preferable to either party for business reasons. IQVIA got to end litigation that was costing it millions in legal fees annually and that had uncertain outcomes. Veeva avoided a potentially crushing damages award and the public admission of wrongdoing. Neither side declared victory because the real value wasn’t in monetary damages—it was in the ability to move forward and, crucially, to work together on new terms.
What New Arrangements Did Veeva And IQVIA Establish After The Settlement?
Perhaps the most significant aspect of the settlement was that rather than ending their relationship, Veeva and IQVIA actually formalized a new business partnership. Both companies established master data and software third-party access agreements that now govern when and how they can share data and software access with each other. This is an important safeguard: if unauthorized access was a concern, the new agreements spell out exactly what access is authorized, under what terms, and with what controls. These agreements represent a shift from implicit or disputed access rights to explicit contractual terms. Instead of IQVIA’s data being off-limits or subject to litigation-threatening disputes, both companies now operate under clear rules. This is more efficient for both sides and better for their mutual customers, who benefit from improved data sharing and integration between the two platforms.
A pharmaceutical company that uses both Veeva’s CRM software and IQVIA’s data products can now expect better integration and fewer restrictions on how the two systems can communicate. However, the existence of these new agreements also creates transparency risks. Both companies now have contractually documented evidence of what data is shared, with whom, and for what purpose. This documentation could be subpoenaed in future disputes or regulatory investigations. Additionally, the agreements presumably include confidentiality and non-disparagement clauses that would prevent either company from publicly discussing the details of what access they have to each other’s systems or data. For customers, this creates some uncertainty: they know data sharing is happening, but the terms are confidential.
What Does This Settlement Mean For Data Security In The Pharmaceutical And Life Sciences Industry?
The Veeva-IQVIA settlement sends a signal to the entire life sciences technology industry that data access disputes will be taken seriously and resolved through major litigation if necessary. Companies that suspect unauthorized data access now have a precedent showing that pursuing claims is feasible, even if it takes eight years and millions in legal fees. Conversely, companies considering unauthorized access know that getting caught could lead to years of litigation, public disputes, and the need to fundamentally restructure business relationships.
The settlement also normalizes the idea that data sharing between competitors, when properly governed by contract, is acceptable and even beneficial. Rather than treating all competitor data as off-limits, the Veeva-IQVIA resolution shows that with the right agreements in place, competitors in the same industry can share data responsibly. This is a positive development for innovation, as it allows companies to build more integrated products and offer customers better competitive intelligence.
What Lessons Does This Case Offer For Companies Managing Proprietary Data?
For any company in the life sciences sector—or any industry where proprietary data is a competitive asset—the Veeva-IQVIA case illustrates the importance of contractual clarity around data access. If you have proprietary data that competitors might want to access, you need explicit agreements with customers and partners that define the boundaries of what they can do with that data and whom they can share it with. Implicit understandings don’t hold up well in litigation.
Looking forward, the settlement may encourage more formal data partnerships in the pharmaceutical technology space. Rather than each company guarding its data jealously and suing when boundaries are crossed, industry players may increasingly negotiate master data agreements upfront that clarify access rights and reduce litigation risk. This could lead to a more competitive and innovative market overall, where companies compete on product quality and service rather than on who controls proprietary data access. The eight-year legal battle between Veeva and IQVIA may accelerate the industry toward this more transparent and contractually-governed future.
You Might Also Like
- Lawsuit Claims 23andMe Sold Ancestry Data to Pharmaceutical Firms Before Filing for Bankruptcy
- Lawsuit Claims Whoop Fitness Tracker Shared Heart Rate Variability Data With Life Insurers
- Lawsuit Claims IBM Watson Health Sold Patient Imaging Data Without Hospital System Consent